Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunome (IMNM) Total Current Liabilities (2023 - 2025)

Immunome (IMNM) has disclosed Total Current Liabilities for 3 consecutive years, with $45.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities fell 17.16% year-over-year to $45.0 million, compared with a TTM value of $45.0 million through Dec 2025, down 17.16%, and an annual FY2025 reading of $45.0 million, down 17.16% over the prior year.
  • Total Current Liabilities was $45.0 million for Q4 2025 at Immunome, up from $31.4 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $54.3 million in Q4 2024 and bottomed at $21.8 million in Q4 2023.
  • Average Total Current Liabilities over 3 years is $32.6 million, with a median of $30.8 million recorded in 2024.
  • The sharpest move saw Total Current Liabilities surged 148.78% in 2024, then tumbled 42.66% in 2025.
  • Year by year, Total Current Liabilities stood at $21.8 million in 2023, then skyrocketed by 148.78% to $54.3 million in 2024, then dropped by 17.16% to $45.0 million in 2025.
  • Business Quant data shows Total Current Liabilities for IMNM at $45.0 million in Q4 2025, $31.4 million in Q3 2025, and $22.9 million in Q2 2025.